Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free KALV Stock Alerts

KalVista Pharmaceuticals (KALV) Financials

KalVista Pharmaceuticals logo
$26.71 +0.05 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$26.66 -0.05 (-0.18%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for KalVista Pharmaceuticals

Annual Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -25 -11 -19 -16 -21 -29 -48 -82 -93 -127 -183
Consolidated Net Income / (Loss)		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Net Income / (Loss) Continuing Operations		 -25 -11 -19 -16 -21 -29 -48 -82 -93 -127 -183
Total Pre-Tax Income 		-25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -180
Total Operating Income		 -21 -15 -22 -19 -30 -41 -58 -97 -111 -140 -188
Total Gross Profit		 0.03 2.13 1.50 8.39 16 13 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.03 2.13 1.50 8.39 16 13 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 17 24 27 46 53 58 97 111 140 188
Selling, General & Admin Expense		 4.87 2.65 11 8.86 11 13 17 26 31 54 116
Research & Development Expense		 16 15 13 18 35 40 41 70 80 86 72
Total Other Income / (Expense), net		 -3.81 3.75 3.74 2.90 9.13 11 12 14 18 14 7.94
Interest Expense		 4.37 - - - - - - - - 0.00 5.79
Interest & Investment Income		 0.01 0.05 0.04 0.08 1.40 1.83 0.90 1.09 2.23 3.90 6.44
Other Income / (Expense), net		 0.55 3.70 3.70 2.82 7.73 9.46 9.08 13 16 9.91 7.29
Income Tax Expense		 - - - 0.00 0.12 -0.12 0.00 0.00 0.00 0.00 3.39
Basic Earnings per Share		 ($1.30) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Weighted Average Basic Shares Outstanding		 26.33M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.47M 27.89M 36.79M 49.65M
Diluted Earnings per Share		 ($1.30) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Weighted Average Diluted Shares Outstanding		 26.33M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.47M 27.89M 36.79M 49.65M
Weighted Average Basic & Diluted Shares Outstanding		 19.08M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.57M 34.23M 42.74M 49.95M

Quarterly Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 1/31/2023 4/30/2023 7/31/2023 10/31/2023 9/30/2024 4/30/2024 7/31/2024 10/31/2024 9/30/2025 4/30/2025 7/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -26 -25 -28 -39 -45 -40 -42 -49 -52 -60
Consolidated Net Income / (Loss)		 -21 -26 -25 -28 -39 -45 -40 -42 -49 -52 -60
Net Income / (Loss) Continuing Operations		 -21 -26 -25 -28 -39 -45 -40 -42 -49 -52 -60
Total Pre-Tax Income 		-21 -26 -25 -28 -39 -45 -40 -42 -47 -53 -58
Total Operating Income		 -27 -32 -29 -30 -43 -48 -44 -46 -46 -55 -59
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 14 - 1.43
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 14 - 1.43
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 14 - 1.43
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 27 32 29 30 43 48 44 46 60 55 60
Selling, General & Admin Expense		 6.88 7.78 9.79 11 25 23 18 29 47 39 45
Research & Development Expense		 20 24 19 19 19 25 27 17 12 16 15
Other Operating Expenses / (Income)		 - - - - 0.00 - 0.00 - 1.23 - 0.59
Total Other Income / (Expense), net		 5.64 5.42 3.78 2.10 4.40 3.81 3.77 3.54 -1.28 1.95 1.07
Interest Expense		 - - - - 0.00 - 0.00 - 4.76 - 3.52
Interest & Investment Income		 0.73 0.81 0.92 0.78 1.58 1.51 1.69 1.36 1.88 1.99 1.85
Other Income / (Expense), net		 4.91 4.61 2.85 1.32 2.82 2.29 2.08 2.19 1.61 2.90 2.74
Income Tax Expense		 - - - - 0.00 - 0.00 - 2.16 - 2.16
Basic Earnings per Share		 ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99) ($1.12)
Weighted Average Basic Shares Outstanding		 28.28M 27.89M 34.41M 34.57M 46.59M 36.79M 46.23M 46.70M 53.88M 49.65M 53.50M
Diluted Earnings per Share		 ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99) ($1.12)
Weighted Average Diluted Shares Outstanding		 28.28M 27.89M 34.41M 34.57M 46.59M 36.79M 46.23M 46.70M 53.88M 49.65M 53.50M
Weighted Average Basic & Diluted Shares Outstanding		 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 50.55M 49.95M 50.52M

Annual Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Change in Cash & Equivalents		 50 19 9.19 18 -19 -16 35 -20 26 -24 100
Net Cash From Operating Activities		 -21 -13 -24 11 -36 -45 -30 -78 -75 -89 -153
Net Cash From Continuing Operating Activities		 -21 -13 -24 11 -36 -45 -30 -79 -75 -89 -153
Net Income / (Loss) Continuing Operations		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Consolidated Net Income / (Loss)		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Depreciation Expense		 0.13 0.03 0.04 0.18 0.38 0.51 0.54 0.56 0.72 0.82 0.94
Amortization Expense		 0.78 - - 0.00 0.00 0.19 0.69 2.57 0.99 0.09 5.89
Non-Cash Adjustments To Reconcile Net Income		 3.67 -1.68 -0.95 0.73 -2.02 -1.55 14 13 6.21 30 16
Changes in Operating Assets and Liabilities, net		 -0.60 -0.07 -4.21 25 -14 -15 0.89 -12 9.73 6.99 7.78
Net Cash From Investing Activities		 -1.37 -0.01 34 -1.43 -69 17 -148 58 41 -85 91
Net Cash From Continuing Investing Activities		 -1.37 -0.01 34 -1.43 -69 17 -148 58 41 -85 91
Purchase of Property, Plant & Equipment		 -0.66 -0.01 - -1.43 -1.08 -0.22 -0.08 -0.93 -1.20 -0.44 -0.93
Purchase of Investments		 - - - 0.00 -80 -50 -201 -137 -98 -189 -31
Sale and/or Maturity of Investments		 - - - 0.00 12 67 54 196 141 105 123
Net Cash From Financing Activities		 72 33 0.00 8.99 88 12 212 1.58 58 151 160
Net Cash From Continuing Financing Activities		 72 33 0.00 8.99 88 12 212 1.58 58 151 160
Issuance of Common Equity		 68 0.00 - 9.14 88 12 212 1.58 58 151 62
Other Financing Activities, net		 0.16 - 0.00 - - - - - - 0.00 98
Effect of Exchange Rate Changes		 - -0.60 -1.16 - -1.21 0.26 0.51 -1.17 1.24 -1.21 2.64

Quarterly Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 1/31/2023 4/30/2023 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025
Net Change in Cash & Equivalents		 46 -29 -6.83 8.26 -35 8.73 0.06 9.73 126 -36 -7.31
Net Cash From Operating Activities		 -9.29 -23 -27 -20 -28 -15 -40 -40 -33 -40 -55
Net Cash From Continuing Operating Activities		 -9.29 -23 -27 -20 -28 -15 -40 -40 -33 -40 -55
Net Income / (Loss) Continuing Operations		 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52 -60
Consolidated Net Income / (Loss)		 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52 -60
Depreciation Expense		 0.20 0.19 0.19 0.20 0.21 0.22 0.22 0.23 0.23 0.26 0.25
Amortization Expense		 0.21 0.10 0.06 0.02 0.01 0.00 0.01 0.01 2.93 2.95 3.45
Non-Cash Adjustments To Reconcile Net Income		 3.79 -2.12 2.55 -0.31 0.17 27 2.30 2.18 7.92 3.52 7.42
Changes in Operating Assets and Liabilities, net		 7.81 5.50 -4.22 7.92 1.07 2.22 -2.31 0.21 4.76 5.13 -5.53
Net Cash From Investing Activities		 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52 -3.33 21
Net Cash From Continuing Investing Activities		 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52 -3.33 21
Purchase of Property, Plant & Equipment		 -0.02 -0.07 -0.01 -0.21 -0.11 -0.12 -0.09 -0.20 -0.13 -0.52 -0.44
Purchase of Investments		 -54 -34 -26 -3.77 -18 -142 -0.98 -0.00 -6.56 -23 -20
Sale and/or Maturity of Investments		 51 28 45 33 12 15 38 49 15 20 42
Net Cash From Financing Activities		 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152 4.66 23
Net Cash From Continuing Financing Activities		 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152 4.66 23
Issuance of Common Equity		 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 57 1.85 1.29
Other Financing Activities, net		 - - - - - - 0.00 - - 2.81 22
Effect of Exchange Rate Changes		 0.46 0.07 0.08 -0.60 -0.62 -0.07 0.12 0.41 -1.25 3.36 2.72

Annual Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 12/31/2024 4/30/2025
Total Assets		 57 25 34 61 118 93 272 204 183 295 251
Total Current Assets		 55 25 34 59 116 89 264 194 172 286 242
Cash & Equivalents		 54 22 31 51 32 16 51 31 56 182 132
Short-Term Investments		 - - - - 69 52 198 135 93 86 89
Accounts Receivable		 - - - - - - - - - 0.00 0.00
Prepaid Expenses		 1.22 0.67 0.70 1.49 3.42 4.46 4.92 13 6.38 6.22 20
Other Current Assets		 - 0.36 0.30 6.83 11 17 10 14 17 11 1.38
Plant, Property, & Equipment, net		 0.81 0.07 0.10 1.84 2.41 2.04 1.79 2.18 2.95 1.88 1.99
Total Noncurrent Assets		 1.04 0.00 0.05 0.17 0.17 1.79 5.96 8.06 7.93 6.95 7.09
Other Noncurrent Operating Assets		 0.99 - 0.05 0.17 0.17 1.79 5.96 8.06 7.93 6.95 7.09
Total Liabilities & Shareholders' Equity		 57 25 34 61 118 93 272 204 183 295 251
Total Liabilities		 7.48 3.25 3.02 34 21 8.78 15 19 22 130 155
Total Current Liabilities		 4.27 3.25 3.02 23 18 7.72 9.77 12 15 26 45
Accounts Payable		 1.46 1.14 1.15 1.43 2.86 1.68 1.98 3.64 4.82 5.73 4.88
Accrued Expenses		 1.33 2.11 1.87 3.09 5.65 5.46 6.93 6.96 9.13 19 27
Current Deferred Revenue		 0.03 - - 18 9.55 - - - - 0.00 11
Other Current Liabilities		 - - - - 0.00 0.59 0.86 0.98 1.09 1.45 1.98
Total Noncurrent Liabilities		 3.21 0.00 0.00 11 3.34 1.06 5.05 7.21 7.15 104 110
Capital Lease Obligations		 - - - 0.06 - - - - - - 4.33
Other Noncurrent Operating Liabilities		 - - - - 0.00 1.06 5.05 7.21 7.15 104 106
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Equity & Noncontrolling Interests		 49 -37 31 27 97 84 257 185 161 164 95
Total Preferred & Common Equity		 49 -37 31 27 97 84 257 185 161 164 95
Total Common Equity		 49 -37 31 27 97 84 257 185 161 164 95
Common Stock		 122 0.22 90 100 191 207 426 439 507 747 754
Retained Earnings		 -73 -37 -56 -72 -92 -122 -168 -250 -343 -580 -653
Accumulated Other Comprehensive Income / (Loss)		 - -0.08 -2.64 -1.11 -1.93 -1.88 -1.43 -3.86 -3.06 -2.42 -5.21

Quarterly Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 7/31/2022 10/31/2022 1/31/2023 7/31/2023 10/31/2023 1/31/2024 7/31/2024 10/31/2024 9/30/2025 7/31/2025
Total Assets		 182 163 203 160 139 114 200 161 340 216
Total Current Assets		 170 151 192 150 129 104 192 152 325 206
Cash & Equivalents		 38 39 85 49 58 23 32 42 243 124
Short-Term Investments		 104 84 87 74 46 53 142 94 66 67
Accounts Receivable		 - - - - - - - - 5.78 1.93
Prepaid Expenses		 11 8.91 8.56 7.53 5.46 5.51 7.45 5.41 8.49 12
Other Current Assets		 17 20 12 19 20 23 9.91 11 1.34 0.56
Plant, Property, & Equipment, net		 3.03 3.06 3.04 2.81 2.50 2.42 2.10 2.04 3.19 2.07
Total Noncurrent Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 12 7.54
Other Noncurrent Operating Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 12 7.54
Total Liabilities & Shareholders' Equity		 182 163 203 160 139 114 200 161 340 216
Total Liabilities		 18 19 19 21 24 25 27 27 323 175
Total Current Liabilities		 9.73 11 12 14 18 19 22 22 45 38
Accounts Payable		 2.91 3.38 1.70 5.06 4.90 3.10 11 5.20 8.07 5.87
Accrued Expenses		 5.83 6.91 8.85 7.95 12 15 10 15 21 19
Current Deferred Revenue		 - - - - - - - - 12 11
Other Current Liabilities		 1.00 1.03 1.06 1.12 1.15 1.19 1.26 1.54 4.72 2.12
Total Noncurrent Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 4.68 278 136
Capital Lease Obligations		 - - - - - - - 4.68 - 4.02
Other Noncurrent Operating Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 - 139 132
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Equity & Noncontrolling Interests		 165 144 184 139 114 89 173 134 17 41
Total Preferred & Common Equity		 165 144 184 139 114 89 173 134 17 41
Total Common Equity		 165 144 184 139 114 89 173 134 17 41
Common Stock		 442 445 505 511 514 517 686 689 763 760
Retained Earnings		 -273 -295 -317 -368 -396 -425 -510 -552 -739 -713
Accumulated Other Comprehensive Income / (Loss)		 -4.15 -5.33 -3.54 -2.89 -3.47 -3.29 -2.87 -2.70 -6.73 -6.39

Annual Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 7,255.17% -29.49% 458.11% 92.13% -21.31% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -65.30% 41.49% -62.39% 15.55% -38.23% -39.86% -56.82% -68.63% -16.35% -38.74% -34.13%
EBIT Growth		 -66.84% 43.93% -62.28% 14.76% -39.04% -40.66% -57.20% -70.82% -14.04% -37.21% -38.43%
NOPAT Growth		 -80.15% 27.83% -47.15% 16.27% -59.42% -35.93% -42.90% -66.80% -14.76% -26.67% -33.86%
Net Income Growth		 -85.99% 53.97% -62.67% 15.04% -31.71% -39.87% -58.83% -78.05% -12.83% -36.31% -44.85%
EPS Growth		 94.04% 53.97% 82.92% 65.77% 9.80% -18.84% -47.56% -38.84% 0.89% -3.30% -7.27%
Operating Cash Flow Growth		 -85.40% 36.94% -80.31% 144.51% -444.43% -23.24% 32.68% -158.97% 3.68% -18.56% -71.36%
Free Cash Flow Firm Growth		 -147.54% 37.78% -59.43% 166.37% -473.15% -20.24% 32.41% -138.79% 10.08% -17.73% 90.43%
Invested Capital Growth		 109.46% -283.56% 240.67% -6,339.52% 82.69% 493.76% -48.47% 128.59% -38.33% -132.78% -5,605.28%
Revenue Q/Q Growth		 0.00% 7,255.17% -57.42% 130.73% -10.60% 7.61% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -2.11% 46.26% -85.08% 18.43% -58.23% 5.53% -24.93% -10.08% -3.42% -17.29% -1.74%
EBIT Q/Q Growth		 -6.23% 46.50% -86.50% 18.10% -57.46% 5.22% -25.40% -9.76% -2.96% -17.08% -3.41%
NOPAT Q/Q Growth		 -9.09% 29.28% -35.01% 10.13% -38.50% 5.37% -18.60% -9.98% -4.64% -13.52% -3.62%
Net Income Q/Q Growth		 -3.95% 48.02% -96.44% 18.43% -60.78% 6.25% -22.11% -12.51% -2.42% -16.94% -4.31%
EPS Q/Q Growth		 -42.86% 48.02% -249.22% 15.00% -84.00% 5.20% -14.15% -10.16% 6.72% -10.26% 1.86%
Operating Cash Flow Q/Q Growth		 -3.63% 30.86% -16.99% -23.89% -14.32% -4.93% 4.96% -25.23% 5.23% 7.78% -19.79%
Free Cash Flow Firm Q/Q Growth		 0.00% 35.23% -25.90% -34.72% -6.57% -2.96% -1.35% -17.88% 4.62% 4.61% 17.10%
Invested Capital Q/Q Growth		 119.70% 0.00% -72.09% 20.99% 41.86% 58.74% 0.12% 43.69% -8.67% -129.38% -16.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -67,493.10% -536.94% -1,236.64% -187.12% -134.63% -239.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -72,537.93% -711.72% -1,485.31% -222.84% -184.91% -319.41% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -70,641.38% -538.49% -1,239.30% -189.27% -136.97% -244.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -85,675.86% -536.15% -1,236.90% -188.29% -129.08% -229.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.60% 99.58% 100.00% 100.00% 100.00% 100.00% 101.88%
Interest Burden Percent		 121.28% 99.56% 99.81% 99.48% 93.68% 94.11% 94.68% 98.69% 97.65% 97.02% 99.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -28,692.29% 0.00% 0.00% -474.27% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -28,681.04% 0.00% 0.00% -473.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 28,621.86% 0.00% 0.00% 442.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -968.84% -32.30% -70.44% -53.96% -33.58% -32.26% -27.13% -37.23% -53.69% -68.90% -121.50%
Cash Return on Invested Capital (CROIC)		 -11,242.60% 0.00% -4,318.91% 0.00% 0.00% -302.31% -269.71% -576.37% -460.81% 0.00% 0.00%
Operating Return on Assets (OROA)		 -64.59% -28.17% -63.09% -33.19% -24.61% -29.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -78.34% -28.05% -62.97% -33.02% -23.19% -27.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -968.84% -5.56% 7.71% -53.96% -33.58% -32.26% -27.13% -37.23% -53.69% -68.90% -121.50%
Return on Equity Simple (ROE_SIMPLE)		 -50.39% 30.81% -59.38% -57.99% -21.52% -34.76% -17.98% -44.49% -57.70% -61.30% -192.31%
Net Operating Profit after Tax (NOPAT)		 -15 -11 -16 -13 -21 -28 -41 -68 -78 -98 -132
NOPAT Margin		 -50,776.55% -498.20% -1,039.71% -155.99% -129.44% -223.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -310.17% -2.28% -11.25% -6.64% 0.08% -0.88% -3.60% -7.09% -9.69% -15.75% -24.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - -131.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 16,779.31% 124.38% 743.15% 105.58% 67.75% 102.67% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 55,858.62% 687.34% 842.15% 217.26% 217.16% 316.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 72,637.93% 811.72% 1,585.31% 322.84% 284.91% 419.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -11 -19 -16 -22 -31 -49 -83 -95 -131 -181
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -11 -19 -16 -22 -30 -48 -80 -93 -130 -174
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.93 0.00 2.32 3.81 4.10 2.32 2.36 1.69 1.81 2.32 7.18
Price to Tangible Book Value (P/TBV)		 1.93 0.00 2.32 3.81 4.10 2.32 2.36 1.69 1.81 2.32 7.18
Price to Revenue (P/Rev)		 3,285.77 9.04 48.36 12.37 24.60 15.34 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 316.26 0.00 110.84 0.00 0.00 7.92 43.33 7.74 12.20 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,592.19 26.31 27.78 6.32 18.35 10.01 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 5.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Long-Term Debt to Equity		 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Financial Leverage		 -1.27 -1.00 -1.00 -1.40 -1.22 -0.93 -0.93 -0.94 -0.91 -0.98 -1.39
Leverage Ratio		 12.37 1.15 1.12 1.63 1.45 1.17 1.07 1.08 1.12 1.14 1.61
Compound Leverage Factor		 15.00 1.15 1.12 1.63 1.36 1.10 1.01 1.06 1.09 1.10 1.60
Debt to Total Capital		 8.55% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.34%
Short-Term Debt to Total Capital		 2.70% 0.00% 0.00% 0.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 5.85% 0.00% 0.00% 0.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 272.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.45% -172.65% 100.00% 98.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.66%
Debt to EBITDA		 -0.24 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Net Debt to EBITDA		 2.51 0.00 0.00 3.23 0.00 0.00 0.00 0.00 0.00 0.00 1.24
Long-Term Debt to EBITDA		 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Debt to NOPAT		 -0.31 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.03
Net Debt to NOPAT		 3.34 0.00 0.00 3.88 0.00 0.00 0.00 0.00 0.00 0.00 1.64
Long-Term Debt to NOPAT		 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03
Altman Z-Score		 5.73 1.05 11.53 0.18 10.54 11.55 24.24 7.98 4.58 6.38 -2.44
Noncontrolling Interest Sharing Ratio		 0.00% 82.77% 110.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.86 7.59 11.33 2.56 6.40 11.49 27.04 16.73 11.46 9.90 5.35
Quick Ratio		 12.58 6.70 10.26 2.20 5.58 8.77 25.47 14.36 9.94 9.23 4.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -10 -16 11 -40 -48 -33 -78 -70 -83 -8.50
Operating Cash Flow to CapEx		 -3,165.86% -119,600.00% 0.00% 739.87% -3,364.01% -20,370.91% -36,793.90% -8,392.48% -6,292.73% -20,142.44% -16,459.31%
Free Cash Flow to Firm to Interest Expense		 -3.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.47
Operating Cash Flow to Interest Expense		 -4.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.43
Operating Cash Flow Less CapEx to Interest Expense		 -4.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.59
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.05 0.05 0.18 0.18 0.12 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.06 4.85 17.59 8.68 7.59 5.70 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.15 -0.27 0.38 -24 -4.07 16 8.26 19 12 -3.82 -121
Invested Capital Turnover		 -0.04 -34.97 27.60 -0.73 -1.17 2.12 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.69 -0.41 0.65 -24 19 20 -7.77 11 -7.24 -15 -123
Enterprise Value (EV)		 46 56 42 53 296 127 358 146 142 268 468
Market Capitalization		 95 19 73 104 397 195 607 312 291 479 685
Book Value per Share		 $1.87 ($1.41) $3.23 $2.52 $5.61 $4.69 $10.58 $7.54 $4.71 $4.90 $1.92
Tangible Book Value per Share		 $1.87 ($1.41) $3.23 $2.52 $5.61 $4.69 $10.58 $7.54 $4.71 $4.90 $1.92
Total Capital		 54 21 31 28 97 84 257 185 161 207 100
Total Debt		 4.61 0.00 0.00 0.28 0.00 0.00 0.00 0.00 0.00 0.00 4.33
Total Long-Term Debt		 3.15 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 4.33
Net Debt		 -49 -22 -31 -51 -101 -68 -249 -166 -149 -210 -216
Capital Expenditures (CapEx)		 0.66 0.01 -0.07 1.43 1.08 0.22 0.08 0.93 1.20 0.44 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.59 -0.34 0.23 -15 -3.32 13 5.56 16 7.92 -7.52 -24
Debt-free Net Working Capital (DFNWC)		 52 21 31 36 97 81 254 182 157 203 197
Net Working Capital (NWC)		 51 21 31 36 97 81 254 182 157 203 197
Net Nonoperating Expense (NNE)		 10 0.81 2.97 2.71 -0.06 0.74 5.70 15 15 28 52
Net Nonoperating Obligations (NNO)		 -49 -22 -31 -51 -101 -68 -249 -166 -149 -210 -216
Total Depreciation and Amortization (D&A)		 0.91 0.03 0.04 0.18 0.38 0.71 1.22 3.13 1.71 0.91 6.83
Debt-free, Cash-free Net Working Capital to Revenue		 -5,496.55% -16.03% 15.29% -174.77% -20.57% 104.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 179,755.17% 1,004.31% 2,073.14% 433.46% 604.54% 638.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 174,737.93% 1,004.31% 2,073.14% 430.83% 604.54% 638.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Adjusted Weighted Average Basic Shares Outstanding		 1.88M 591.30K 9.71M 10.80M 17.39M 17.85M 24.44M 24.47M 27.89M 36.79M 49.65M
Adjusted Diluted Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Adjusted Weighted Average Diluted Shares Outstanding		 1.88M 591.30K 9.71M 10.80M 17.39M 17.85M 24.44M 24.47M 27.89M 36.79M 49.65M
Adjusted Basic & Diluted Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.36M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.57M 34.23M 42.74M 49.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -11 -16 -13 -21 -28 -41 -68 -78 -98 -132
Normalized NOPAT Margin		 -50,776.55% -498.20% -1,039.71% -155.99% -129.44% -223.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -85,675.86% -536.15% -1,236.90% -188.29% -128.31% -230.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.24
NOPAT to Interest Expense		 -3.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.75
EBIT Less CapEx to Interest Expense		 -4.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.40
NOPAT Less CapEx to Interest Expense		 -3.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.91
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 1/31/2023 4/30/2023 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 1.35% -13.00% -14.30% -26.80% -36.42% -71.24% -61.27% -53.83% -34.44% -6.48% -25.44%
EBIT Growth		 3.04% -11.21% -12.70% -25.19% -34.84% -70.25% -60.58% -53.47% -44.10% -12.92% -33.54%
NOPAT Growth		 -0.98% -18.34% -10.55% -14.92% -23.03% -52.72% -51.98% -54.01% -29.53% -13.57% -33.46%
Net Income Growth		 5.18% -9.09% -9.87% -24.23% -36.26% -69.74% -59.75% -52.87% -67.11% -16.97% -48.59%
EPS Growth		 18.48% 24.49% 21.28% 11.11% -12.00% -43.24% -17.57% -13.75% -9.52% 6.60% -28.74%
Operating Cash Flow Growth		 33.96% 15.50% -17.54% 3.73% -196.81% 33.27% -50.47% -99.96% -18.53% -167.22% -35.51%
Free Cash Flow Firm Growth		 21.64% 49.08% 48.57% 52.02% -26.94% -23.26% 3.92% -124.37% 469.68% 445.69% 875.23%
Invested Capital Growth		 -2.97% -38.33% -28.53% -47.66% 1.89% -132.78% -109.16% -74.36% -898.18% -5,605.28% -9,856.28%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.80% -24.07% 3.14% -8.55% -4.58% -55.73% 8.78% -3.55% 8.60% -23.34% -7.47%
EBIT Q/Q Growth		 2.96% -23.05% 3.22% -8.33% -4.52% -55.36% 8.72% -3.54% 1.86% -21.75% -7.94%
NOPAT Q/Q Growth		 -4.10% -17.75% 8.30% -2.24% -11.45% -46.16% 8.75% -3.61% 6.27% -28.15% -7.23%
Net Income Q/Q Growth		 4.29% -23.48% 3.76% -9.22% -4.98% -53.81% 9.42% -4.51% -14.77% -7.66% -15.07%
EPS Q/Q Growth		 16.67% 1.33% 0.00% -8.11% -5.00% -26.19% 17.92% -4.60% -1.10% -7.61% -13.13%
Operating Cash Flow Q/Q Growth		 54.89% -143.69% -18.09% 25.83% -39.07% 45.21% -166.27% 1.44% 17.56% -23.51% -35.03%
Free Cash Flow Firm Q/Q Growth		 16.04% 18.96% 6.83% 24.31% -122.11% 21.31% 27.37% -76.76% 465.97% -2.43% 22.83%
Invested Capital Q/Q Growth		 -40.78% -8.67% 38.01% -29.88% 15.28% -129.38% 61.43% 296.27% -3,688.34% -16.54% -21.31%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,686.40%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,138.08%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,945.72%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,214.31%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 109.60% 98.39% 103.72%
Interest Burden Percent		 96.68% 97.02% 96.48% 97.27% 97.70% 96.72% 95.98% 96.89% 103.38% 101.82% 102.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50% -121.50% -190.18%
Cash Return on Invested Capital (CROIC)		 -569.64% -460.81% -379.18% -438.79% -674.43% 0.00% 0.00% -1,577.97% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.07%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -28.91%
Return on Common Equity (ROCE)		 -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50% -121.50% -190.18%
Return on Equity Simple (ROE_SIMPLE)		 -49.18% 0.00% -68.31% -87.88% -122.26% 0.00% -82.04% -116.71% -121.18% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -22 -20 -21 -23 -34 -31 -32 -30 -39 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,896.66%
Net Nonoperating Expense Percent (NNEP)		 -1.33% -2.60% -3.73% -6.06% -4.71% -5.97% -6.38% -8.71% -11.37% -6.52% -10.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -26.20% - - - -20.11% -38.63% -92.18%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,133.45%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,063.25%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,238.08%
Earnings before Interest and Taxes (EBIT)		 -22 -27 -26 -28 -30 -46 -42 -44 -43 -52 -56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -27 -26 -28 -30 -46 -42 -43 -40 -49 -53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03 7.18 16.69
Price to Tangible Book Value (P/TBV)		 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03 7.18 16.69
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 477.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.90 12.20 13.84 16.76 36.12 0.00 0.00 108.17 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 346.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 152.73
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.05 0.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.05 0.10
Financial Leverage		 -0.93 -0.91 -0.87 -0.87 -0.91 -0.98 -0.95 -0.94 -1.39 -1.39 -1.69
Leverage Ratio		 1.09 1.12 1.13 1.17 1.16 1.14 1.16 1.21 1.67 1.61 1.95
Compound Leverage Factor		 1.06 1.09 1.09 1.14 1.14 1.10 1.11 1.17 1.73 1.64 2.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90% 4.34% 8.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90% 4.34% 8.97%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.63% 97.10% 95.66% 91.03%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02 -0.02
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.82 1.46 1.24 1.02
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02 -0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03 -0.03 -0.03
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.96 1.64 1.32
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03 -0.03 -0.03
Altman Z-Score		 4.71 5.81 7.14 3.50 7.69 7.56 10.36 5.19 -0.49 -0.75 -2.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.55 11.46 10.60 7.25 5.44 9.90 8.55 6.87 10.44 5.35 5.37
Quick Ratio		 14.79 9.94 8.72 5.81 3.95 9.23 7.78 6.13 9.89 4.88 5.04
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -15 -14 -11 -23 -18 -13 -24 87 85 104
Operating Cash Flow to CapEx		 -61,926.67% -32,805.80% -445,500.00% -9,670.73% -25,064.55% -12,381.15% -47,317.65% -19,624.75% -25,733.07% -7,837.67% -12,471.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.50 0.00 29.49
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.50 0.00 -15.47
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.54 0.00 -15.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 13 12 16 11 13 -3.82 -1.47 2.89 -104 -121 -147
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Increase / (Decrease) in Invested Capital		 -0.39 -7.24 -6.42 -10 0.24 -15 -18 -8.38 -117 -123 -145
Enterprise Value (EV)		 24 142 223 189 469 268 447 313 191 468 493
Market Capitalization		 196 291 346 292 545 479 621 444 440 685 681
Book Value per Share		 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94 $1.92 $0.82
Tangible Book Value per Share		 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94 $1.92 $0.82
Total Capital		 184 161 139 114 89 207 173 139 149 100 45
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34 4.33 4.02
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34 4.33 4.02
Net Debt		 -172 -149 -123 -103 -76 -210 -174 -131 -249 -216 -187
Capital Expenditures (CapEx)		 0.02 0.07 0.01 0.21 0.11 0.12 0.09 0.20 0.13 0.52 0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 8.84 7.92 12 7.68 9.39 -7.52 -5.05 -5.67 -11 -24 -24
Debt-free Net Working Capital (DFNWC)		 181 157 136 111 85 203 169 130 242 197 168
Net Working Capital (NWC)		 181 157 136 111 85 203 169 130 242 197 168
Net Nonoperating Expense (NNE)		 2.44 4.10 4.95 6.83 5.82 11 9.49 10 18 14 19
Net Nonoperating Obligations (NNO)		 -172 -149 -123 -103 -76 -210 -174 -131 -249 -216 -187
Total Depreciation and Amortization (D&A)		 0.41 0.29 0.26 0.22 0.21 0.22 0.23 0.23 3.15 3.21 3.70
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,679.10%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11,747.62%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11,747.62%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99) ($1.12)
Adjusted Weighted Average Basic Shares Outstanding		 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M 53.50M
Adjusted Diluted Earnings per Share		 ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99) ($1.12)
Adjusted Weighted Average Diluted Shares Outstanding		 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M 53.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 49.72M 49.95M 50.52M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -22 -20 -21 -23 -34 -31 -32 -30 -39 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,896.66%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,063.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.06 0.00 -15.98
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.58 0.00 -11.73
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.11 0.00 -16.10
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.62 0.00 -11.85
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

KalVista Pharmaceuticals, Inc. (KALV) continues to operate as a clinical-stage biotech with limited revenue and ongoing R&D. The last four years of quarterly data show a pattern of ongoing net losses and heavy cash burn from operations, offset by periodic equity financing and some investment-related cash inflows that have helped preserve liquidity. Here are the most notable trends from the quarterly statements.

  • Equity financing provided a strong liquidity boost in 2025, including a net financing inflow of about $151.8 million in Q3 2025.
  • Cash on hand was notably high in Q3 2025, with cash & equivalents around $243.5 million, giving the company runway to fund ongoing development.
  • Additional equity raises in later quarters contributed to cash reserves: approximately $4.7 million in Q4 2025 and about $1.3 million in Q1 2026 from common stock issuances.
  • Investing activities generated liquidity in several quarters via sale/maturity of investments: about $15.2 million in Q3 2025 and about $20.2 million in Q4 2025.
  • Total current assets generally exceed total current liabilities, indicating short-term liquidity headroom.
  • Q3 2025 showed a sizable cash balance and a mix of investment activity that supported liquidity beyond operating cash flow.
  • Net income has been consistently negative across periods, with Q1 2026 net income around -$60.1 million.
  • Operating cash flow remains negative in multiple quarters, including roughly -$54.5 million in Q1 2026, signaling a high cash burn to fund development and SG&A.
  • Long-term debt remains material (approximately $139 million in Q3 2025), and a sizable accumulated deficit weighs on the equity base.
  • Earnings per share remain deeply negative (Q1 2026 diluted EPS around -$1.12) due to ongoing losses and equity dilution.
05/05/26 05:41 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About KalVista Pharmaceuticals' Financials

When does KalVista Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, KalVista Pharmaceuticals' fiscal year ends in April. Their fiscal year 2025 ended on April 30, 2025.

How has KalVista Pharmaceuticals' net income changed over the last 10 years?

KalVista Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$183.44 million in 2025, rising from -$24.85 million in 2015. The previous period was -$126.64 million in 2024. Find out what analysts predict for KalVista Pharmaceuticals in the coming months.

What is KalVista Pharmaceuticals' operating income?
KalVista Pharmaceuticals' total operating income in 2025 was -$188.00 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $188.00 million
How has KalVista Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, KalVista Pharmaceuticals' total revenue changed from $29 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

How much debt does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals' total liabilities were at $155.38 million at the end of 2025, a 19.1% increase from 2024, and a 1,977.0% increase since 2015.

How much cash does KalVista Pharmaceuticals have?

In the past 10 years, KalVista Pharmaceuticals' cash and equivalents has ranged from $15.79 million in 2020 to $182.33 million in 2024, and is currently $131.62 million as of their latest financial filing in 2025.

How has KalVista Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, KalVista Pharmaceuticals' book value per share changed from 1.87 in 2015 to 1.92 in 2025, a change of 2.4%.


Related Companies

Financial statements for NASDAQ:KALV last updated on 11/26/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel